Cargando…
COVID-19: Coronavirus Vaccine Development Updates
Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. How...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785583/ https://www.ncbi.nlm.nih.gov/pubmed/33424848 http://dx.doi.org/10.3389/fimmu.2020.602256 |
_version_ | 1783632472961974272 |
---|---|
author | Zhao, Jing Zhao, Shan Ou, Junxian Zhang, Jing Lan, Wendong Guan, Wenyi Wu, Xiaowei Yan, Yuqian Zhao, Wei Wu, Jianguo Chodosh, James Zhang, Qiwei |
author_facet | Zhao, Jing Zhao, Shan Ou, Junxian Zhang, Jing Lan, Wendong Guan, Wenyi Wu, Xiaowei Yan, Yuqian Zhao, Wei Wu, Jianguo Chodosh, James Zhang, Qiwei |
author_sort | Zhao, Jing |
collection | PubMed |
description | Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus, Betacoronavirus, this review of the major research progress will provide a reference and new insights into the COVID-19 vaccine design and development. |
format | Online Article Text |
id | pubmed-7785583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77855832021-01-07 COVID-19: Coronavirus Vaccine Development Updates Zhao, Jing Zhao, Shan Ou, Junxian Zhang, Jing Lan, Wendong Guan, Wenyi Wu, Xiaowei Yan, Yuqian Zhao, Wei Wu, Jianguo Chodosh, James Zhang, Qiwei Front Immunol Immunology Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus, Betacoronavirus, this review of the major research progress will provide a reference and new insights into the COVID-19 vaccine design and development. Frontiers Media S.A. 2020-12-23 /pmc/articles/PMC7785583/ /pubmed/33424848 http://dx.doi.org/10.3389/fimmu.2020.602256 Text en Copyright © 2020 Zhao, Zhao, Ou, Zhang, Lan, Guan, Wu, Yan, Zhao, Wu, Chodosh and Zhang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhao, Jing Zhao, Shan Ou, Junxian Zhang, Jing Lan, Wendong Guan, Wenyi Wu, Xiaowei Yan, Yuqian Zhao, Wei Wu, Jianguo Chodosh, James Zhang, Qiwei COVID-19: Coronavirus Vaccine Development Updates |
title | COVID-19: Coronavirus Vaccine Development Updates |
title_full | COVID-19: Coronavirus Vaccine Development Updates |
title_fullStr | COVID-19: Coronavirus Vaccine Development Updates |
title_full_unstemmed | COVID-19: Coronavirus Vaccine Development Updates |
title_short | COVID-19: Coronavirus Vaccine Development Updates |
title_sort | covid-19: coronavirus vaccine development updates |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785583/ https://www.ncbi.nlm.nih.gov/pubmed/33424848 http://dx.doi.org/10.3389/fimmu.2020.602256 |
work_keys_str_mv | AT zhaojing covid19coronavirusvaccinedevelopmentupdates AT zhaoshan covid19coronavirusvaccinedevelopmentupdates AT oujunxian covid19coronavirusvaccinedevelopmentupdates AT zhangjing covid19coronavirusvaccinedevelopmentupdates AT lanwendong covid19coronavirusvaccinedevelopmentupdates AT guanwenyi covid19coronavirusvaccinedevelopmentupdates AT wuxiaowei covid19coronavirusvaccinedevelopmentupdates AT yanyuqian covid19coronavirusvaccinedevelopmentupdates AT zhaowei covid19coronavirusvaccinedevelopmentupdates AT wujianguo covid19coronavirusvaccinedevelopmentupdates AT chodoshjames covid19coronavirusvaccinedevelopmentupdates AT zhangqiwei covid19coronavirusvaccinedevelopmentupdates |